Sec Form 3 Filing - Canan John @ Acasti Pharma Inc. - 2020-04-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Canan John 2. Issuer Name and Ticker or Trading Symbol Acasti Pharma Inc. [ ACST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O ACASTI PHARMA INC., 545 PROMENADE DU CENTROPOLIS, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 04/01/2020 (Street) LAVAL, A8H7T 0A3 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 100,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Share Option (Right to Buy) $ 1.65 ( 8 ) ( 1 ) 02/24/2027 Common Shares 50,000 D Share Option (Right to Buy) $ 1.77 ( 8 ) ( 2 ) 06/14/2027 Common Shares 17,400 D Share Option (Right to Buy) $ 1.77 ( 8 ) ( 3 ) 06/14/2027 Common Shares 11,600 D Share Option (Right to Buy) $ 0.77 ( 8 ) ( 4 ) 07/02/2028 Common Shares 60,283 D Share Option (Right to Buy) $ 1.28 ( 8 ) ( 5 ) 04/15/2029 Common Shares 13,300 D Share Option (Right to Buy) $ 1.28 ( 8 ) ( 6 ) 04/15/2029 Common Shares 45,400 D Share Option (Right to Buy) $ 0.53 ( 8 ) ( 7 ) 03/31/2030 Common Shares 86,000 D Warrants $ 2.15 ( 8 ) 02/21/2017 02/21/2022 Common Shares 17,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Canan John C/O ACASTI PHARMA INC. 545 PROMENADE DU CENTROPOLIS, SUITE 100 LAVAL, A8H7T 0A3 X Signatures /s/ Kelsey Weiner, Attorney-in-Fact 04/01/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents 50,000 common shares underlying 50,000 share options granted on February 24, 2017. These share options vested in 6 equal installments on a quarterly basis starting from February 24, 2017 until August 24, 2018. ( 2 )Represents 17,400 common shares underlying 17,400 share options granted on June 14, 2017. These share options vested in 6 equal installments on a quarterly basis starting from June 14, 2017 until December 14, 2018. ( 3 )Represents 11,600 common shares underlying 11,600 share options granted on June 14, 2017. These share options vested in 6 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2018. ( 4 )Represents 60,283 common shares underlying 60,283 share options granted on July 2, 2018. These share options vested in 6 equal installments on a quarterly basis starting from July 2, 2018 until January 2, 2020. ( 5 )Represents 13,300 common shares underlying 13,300 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020. ( 6 )Represents 45,400 common shares underlying 45,400 share options granted on April 15, 2019. These share options vest in 6 equal installments on a quarterly basis starting from April 15, 2019 until October 15, 2020. ( 7 )Represents 86,000 common shares underlying 86,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a monthly basis starting from March 31, 2020 until March 31, 2021. ( 8 )Canadian dollars.

Remarks: Exhibit List - Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.